Renaissance Technologies (RenTech)'s RNAC Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 67,300 shares of Cartesian Therapeutics, Inc. (RNAC) worth $413,895, representing 0.00% of the portfolio. First purchased in 2024-Q2, this short-term holding has been held for 8 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained this position in RNAC for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 41,100 shares. Largest reduction occurred in Q3 2025, reducing 19,500 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Cartesian Therapeutics (RNAC) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cartesian Therapeutics (RNAC) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +26,200 | Add 63.75% | 67,300 | $6.15 |
| Q4 2025 | +41,100 | New Buy | 41,100 | $7.21 |
| Q3 2025 | -19,500 | Sold Out | 0 | $0.00 |
| Q2 2025 | +19,500 | New Buy | 19,500 | $10.39 |
| Q1 2025 | -13,800 | Sold Out | 0 | $0.00 |
| Q4 2024 | +13,800 | New Buy | 13,800 | $17.91 |
| Q3 2024 | -17,052 | Sold Out | 0 | $0.00 |
| Q2 2024 | +17,052 | New Buy | 17,052 | $27.01 |
Renaissance Technologies (RenTech)'s Cartesian Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Cartesian Therapeutics, Inc. (RNAC) in Q2 2024, acquiring 17,052 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Cartesian Therapeutics, Inc. (RNAC) for 8 quarters since Q2 2024.
Renaissance Technologies (RenTech)'s largest addition to Cartesian Therapeutics, Inc. (RNAC) was in Q4 2025, adding 41,100 shares worth $296,331.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 67,300 shares of Cartesian Therapeutics, Inc. (RNAC), valued at approximately $413,895.
As of the Q1 2026 filing, Cartesian Therapeutics, Inc. (RNAC) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Cartesian Therapeutics, Inc. (RNAC) was 67,300 shares, as reported at the end of Q1 2026.